DNA

Artios Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, United Kingdom and NEW YORK, December 19, 2024 – Artios Pharma Limited (“Artios”), a clinical-stage biotech company led by…

2 weeks ago

Rakovina Therapeutics: Reflecting on 2024 Success and Building Momentum for a Transformative 2025

VANCOUVER, British Columbia, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) a biopharmaceutical…

2 weeks ago

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia

Fast track designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenstrom’s MacroglobulinemiaSAN FRANCISCO, Dec. 19,…

2 weeks ago

Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity

Preclinical Studies Confirmed BP1001-A Mechanism of Action and Therapeutic Potential in Obesity and Type 2 DiabetesHOUSTON, Dec. 19, 2024 (GLOBE…

2 weeks ago

Lab Automation Market to Hit USD 7.71 Billion by 2029 with 6.9% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., Dec. 18, 2024 /PRNewswire/ -- The global lab automation market is expected to reach USD 7.71 Billion by…

3 weeks ago

DNAnexus Recognized by Frost & Sullivan for Ability to Integrate and Synchronize Diverse Clinical and Multi-omics Data

Leading cloud-based enterprise platform for precision health data empowers biopharma companies with actionable insights to accelerate drug discovery and development     SAN ANTONIO,…

3 weeks ago

Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA

- Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell Therapies…

3 weeks ago

Neutrolis Expands Senior Leadership Team to Drive Development of Growing Pipeline of Non-Immunosuppressive Therapies for NET-mediated Autoimmune Diseases

Appointment of seasoned executives with substantial industry expertise strengthens team as the company advances programs into the clinicCAMBRIDGE, Mass., Dec.…

3 weeks ago

Tessera Therapeutics Receives Investment to Develop Curative In Vivo Genetic Treatment for Sickle Cell Disease

Investments of up to $50 million from the Bill & Melinda Gates Foundation to develop globally accessible in vivo genetic…

3 weeks ago